CN116287388A - Identification method, primer pair and kit for cryptococcus - Google Patents
Identification method, primer pair and kit for cryptococcus Download PDFInfo
- Publication number
- CN116287388A CN116287388A CN202310144307.8A CN202310144307A CN116287388A CN 116287388 A CN116287388 A CN 116287388A CN 202310144307 A CN202310144307 A CN 202310144307A CN 116287388 A CN116287388 A CN 116287388A
- Authority
- CN
- China
- Prior art keywords
- cryptococcus
- ura5
- type
- ura5 gene
- primer pair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001337994 Cryptococcus <scale insect> Species 0.000 title claims abstract description 150
- 238000000034 method Methods 0.000 title claims abstract description 50
- 101150044776 URA5 gene Proteins 0.000 claims abstract description 64
- 230000003321 amplification Effects 0.000 claims abstract description 20
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 20
- 238000007480 sanger sequencing Methods 0.000 claims abstract description 16
- 238000012163 sequencing technique Methods 0.000 claims abstract description 16
- 238000003752 polymerase chain reaction Methods 0.000 claims abstract description 5
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 9
- 230000004544 DNA amplification Effects 0.000 claims description 7
- 238000001502 gel electrophoresis Methods 0.000 claims description 7
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000002205 phenol-chloroform extraction Methods 0.000 claims description 4
- 229930024421 Adenine Natural products 0.000 claims description 3
- 229960000643 adenine Drugs 0.000 claims description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 229940104302 cytosine Drugs 0.000 claims description 3
- 229940113082 thymine Drugs 0.000 claims description 3
- 235000011178 triphosphate Nutrition 0.000 claims description 3
- 239000001226 triphosphate Substances 0.000 claims description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 25
- 239000000047 product Substances 0.000 description 15
- 238000001514 detection method Methods 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 9
- 238000007481 next generation sequencing Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 201000007336 Cryptococcosis Diseases 0.000 description 6
- 241000221204 Cryptococcus neoformans Species 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003759 clinical diagnosis Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000007918 pathogenicity Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- -1 phosphoribosyl Chemical group 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010013654 Drug abuse Diseases 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The application relates to an identification method, a primer pair and a kit of cryptococcus, wherein the method comprises the following steps: obtaining genome DNA of a sample to be tested; amplifying the URA5 gene of the genomic DNA by polymerase chain reaction PCR to obtain an amplified product; performing sanger sequencing on the amplification product; determining the type of the cryptococcus based on the 562-locus sequencing result of the URA5 gene. The cryptococcus identification method can determine the secondary type of the cryptococcus based on the primary type of the cryptococcus, and accurately judge the subtype of the cryptococcus, thereby helping to promote early intervention and treatment of diseases caused by the cryptococcus.
Description
Technical Field
The invention belongs to the technical field of fungal etiology detection, and particularly relates to an identification method, a primer pair and a kit of cryptococcus.
Background
Cryptococcus is a fungus that can cause cryptococcosis and belongs to the family Cryptococcus of the phylum Deuteromycotina, class of Bacillus in the mycotaxonomy. Cryptococcosis is a pulmonary or disseminated infectious disease caused by cryptococcus, mainly causing pneumonia, meningitis, skin or visceral infections. Cryptococcus is of a wide variety of genus, with the main species responsible for human infection being Cryptococcus neoformans and Cryptococcus glaucocalycis. There are significant differences in epidemiological and clinical pathogenic processes among different types of cryptococcus, for example, cryptococcus neoformans primarily infect immunosuppressed populations, while cryptococcus gartertiaryana primarily infects immunocompetent populations and predominates in pulmonary infections.
Since the pathogenicity and lethality of different types of cryptococcus are different, the judgment of which cryptococcus causes diseases is important for diagnosis and treatment of cryptococcosis. Therefore, how to identify the type of cryptococcus is a problem to be solved.
Disclosure of Invention
The invention provides an identification method, a primer pair and a kit for cryptococcus, which can accurately identify VGIa type cryptococcus, thereby helping to promote early intervention and treatment of diseases caused by cryptococcus.
In a first aspect, the present application provides a method of identifying cryptococcus, the method comprising: obtaining genome DNA of a sample to be tested; amplifying the URA5 gene of the genomic DNA by polymerase chain reaction PCR to obtain an amplified product; performing sanger sequencing on the amplification product; determining the type of the cryptococcus based on the 562-locus sequencing result of the URA5 gene.
Molecular typing of cryptococcus is generally limited to one-stage typing, i.e., classification of cryptococcus into VGI, VGII, VGIV type cryptococcus, and the like. The inventors found that cryptococcus VGI can be further classified into cryptococcus VGI type VGIa, VGIb, VGIc and cryptococcus VGId type, i.e., two-stage type, based on the previous next generation sequencing (Next Generation Sequencing, NGS) and the analysis results. There is also a clear difference in pathogenicity of cryptococcus of different subtypes. The identification method of the cryptococcus provided by the application can accurately identify the subtype of the cryptococcus, the sequencing result of the 562 locus of the URA5 gene is obtained through the amplification of the URA5 gene by the DNA of the sample to be tested and the sanger sequencing, in other words, whether the cryptococcus is the VGIa type cryptococcus or not can be accurately detected through the sequencing result, thereby helping to judge the type of the cryptococcus causing infection in clinical diagnosis. In addition, the detection method of the cryptococcus can be realized without using complex and expensive instruments and equipment, so that the detection cost of the cryptococcus can be saved, and the use scene of clinical detection can be expanded.
In some embodiments, the determining the type of cryptococcus based on sequencing of position 562 of the URA5 gene comprises: determining the cryptococcus as a VGIa type cryptococcus in the case that the 562 site of the URA5 gene is guanine G; in the case where the 562 locus of the URA5 gene is adenine a, cytosine C or thymine T, the cryptococcus is determined to be a wild-type cryptococcus.
It is understood that wild-type cryptococcus refers to cryptococcus other than cryptococcus of VGIa type. In the embodiment of the application, whether the cryptococcus in the sample to be detected is the VGIa type cryptococcus can be accurately judged by detecting whether 562 locus of the URA5 gene is G, so that diagnosis of the cryptococcus subtype causing infection is facilitated.
In some embodiments, the reactants of the PCR include URA5 forward primers and URA5 reverse primers; wherein the nucleotide sequence of the URA5 forward primer is shown as a Seq ID No.1, and the nucleotide sequence of the URA5 reverse primer is shown as a Seq ID No. 2.
In some embodiments, after obtaining the amplification product, the method further comprises: confirming that the URA5 gene amplification was successful.
In some embodiments, the success of the URA5 gene amplification is confirmed by gel electrophoresis.
In the embodiment of the application, after the amplification product is obtained and before sanger sequencing is carried out, whether amplification is successful or not is confirmed by using a gel electrophoresis method, so that the waste of time and cost caused by unsuccessful amplification, namely sanger sequencing, can be avoided, and the efficiency of cryptococcus typing is improved.
In some embodiments, the obtaining genomic DNA of the test sample comprises: grinding the sample to be tested by a liquid nitrogen grinding method; the genomic DNA was extracted by standard phenol chloroform method.
In some embodiments, the sample to be tested comprises blood and/or body fluid.
In a second aspect, there is provided a primer pair for identifying cryptococcus of VGIa type, comprising a forward primer and a reverse primer, wherein the nucleotide sequence of the forward primer is shown as Seq ID No.1 and the nucleotide sequence of the reverse primer is shown as Seq ID No. 2.
In some embodiments, the primer pair is used to identify position 562 of the URA5 gene sequence of the cryptococcus.
In a third aspect, there is provided a kit for identifying Cryptococcus VGIa, wherein the kit comprises a primer pair according to any of the embodiments of the second aspect.
In some embodiments, the kit further comprises: buffer solution, template DNA, deoxynucleoside triphosphate dNTPs and DNA polymerase.
In a fourth aspect, there is provided the use of a primer pair as in any one of the embodiments of the second aspect for identifying cryptococcus VGIa.
The cryptococcus identification method can accurately judge the type of the cryptococcus by amplifying the URA5 gene of the sample to be detected and detecting the sequence of the specific site by means of sanger sequencing so as to identify the type of the cryptococcus, more specifically, can judge whether the cryptococcus is the VGIa type cryptococcus, thereby realizing the secondary type detection of the cryptococcus, defining the subtype of the cryptococcus, helping to carry out rapid and accurate clinical diagnosis and reducing drug abuse.
Drawings
FIG. 1 is a schematic flow chart of an identification method of Cryptococcus in an embodiment of the present application.
FIG. 2 is another schematic flow chart of a method for determining cryptococcus in accordance with an embodiment of the present application.
FIG. 3 is a gel electrophoresis pattern of an amplification product according to the embodiment of the present application.
FIG. 4 is a graph showing the peak sequence of the wild-type cryptococcus and the VGIa cryptococcus of the present application.
Detailed Description
The technical scheme of the application is further described below in connection with specific embodiments.
The "range" disclosed herein is defined in terms of lower and upper limits, with a given range being defined by the selection of a lower and an upper limit, the selected lower and upper limits defining the boundaries of the particular range. Ranges that are defined in this way can be inclusive or exclusive of the endpoints, and any combination can be made, i.e., any lower limit can be combined with any upper limit to form a range. For example, if ranges of 60-120 and 80-110 are listed for a particular parameter, it is understood that ranges of 60-110 and 80-120 are also contemplated. Furthermore, if the minimum range values 1 and 2 are listed, and if the maximum range values 3,4 and 5 are listed, the following ranges are all contemplated: 1-3, 1-4, 1-5, 2-3, 2-4 and 2-5. In this application, unless otherwise indicated, the numerical range "a-b" represents a shorthand representation of any combination of real numbers between a and b, where a and b are both real numbers. For example, the numerical range "0-5" means that all real numbers between "0-5" have been listed throughout, and "0-5" is simply a shorthand representation of a combination of these values. When a certain parameter is expressed as an integer of 2 or more, it is disclosed that the parameter is, for example, an integer of 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12 or the like.
In the description of the present application, the terms "first," "second," "third," and the like are used for descriptive purposes only and are not to be construed as indicating or implying relative importance.
Reference herein to "comprising" and "including" means open ended, as well as closed ended, unless otherwise noted. For example, the terms "comprising" and "comprises" may mean that other components not listed may be included or included, or that only listed components may be included or included.
The term "or" is inclusive in this application, unless otherwise specified. For example, the phrase "a or B" means "a, B, or both a and B. More specifically, either of the following conditions satisfies the condition "a or B": a is true (or present) and B is false (or absent); a is false (or absent) and B is true (or present); or both A and B are true (or present).
All embodiments and alternative embodiments of the present application may be combined with each other to form new solutions, unless specifically stated otherwise.
First, some terms are briefly introduced:
next generation sequencing (Next Generation Sequencing, NGS) is a high throughput sequencing technology that can rapidly and comprehensively detect DNA mutations in the genome, commonly used for circulating tumor DNA (Circulating Tumor DNA, ctDNA), copy number variation (Copy Number Variations, CNVs) and gene fusion (using RNA sequencing panel). NGS may detect a variety of different types of samples, such as blood, tumor tissue, and bone marrow samples.
Sanger sequencing (Sanger Sequencing) is a method of obtaining a base sequence of a visible DNA, specifically, starting at a certain fixed point according to nucleotides, randomly terminating at a certain specific base, and fluorescence labeling after each base, producing four sets of nucleotides of different lengths ending with Adenine (A), thymine (T), cytosine (C), guanine (G), and then performing polyacrylamide gel electrophoresis (Polyacrylamide Gel Eectrophoresis, PAGE), thereby obtaining a base sequence of a visible DNA. The ability to analyze long and continuous nucleic acid sequences to detect DNA strands to identify mutations by sanger sequencing is one of the important means to achieve molecular typing.
The polymerase chain reaction (Polymerase Chain Reaction, PCR) is a molecular biological technique for amplifying specific DNA fragments, which can be regarded as specific DNA replication in vitro.
Multi-site sequence typing (MultilocusSequence Typing, MLST) is a bacterial typing method based on nucleic acid sequence determination. This method analyzes the variation of the strain by amplifying a plurality of housekeeping gene internal fragments by PCR and determining the sequence thereof. MLST has the advantages of simple operation, capability of rapidly obtaining results and the like.
The Real-time fluorescence quantitative nucleic acid amplification detection system (Real-time Quantitative PCR Detecting System, QPCR) is a method for adding a fluorescent group into a PCR reaction system, monitoring the whole PCR process in Real time by utilizing fluorescent signal accumulation, and finally quantitatively analyzing an unknown template through a standard curve.
URA5 gene: a phosphoribosyl transferase gene of cryptococcus, the nucleotide sequence of which is shown in Seq ID No. 3.
The embodiments of the present application are described below.
Cryptococcus is a fungus that mainly invades the central system of the human body, causing cryptococcosis. Cryptococcus comprises 17 and 8 variants of neutralization, of which novel Cryptococcus is the main pathogenic strain, hereinafter referred to as Cryptococcus. Different cryptococcus pathogenic rates, infected people have obvious differences, and therefore, it is critical for clinical diagnosis to identify which cryptococcus is responsible for the infection. With the improvement of gene detection means, cryptococcus has 8 molecular types: VNI, VNII, VNIII, VNIV, VGI, VGII, VGIII, VGIV. The inventors of the present application have found through NGS in combination with clinical epidemiological analysis that cryptococcus can be further classified into type VGIa, VGIb, VGIc and type VGId cryptococcus, i.e., type two, in addition to the above 8 types of primary classification; in addition, in the infection caused by cryptococcus, the pathogenicity rate, the lethality rate and the clinical manifestation of the cryptococcus of different subtypes are different, so that the detection of the cryptococcus subtype is extremely important in early clinical diagnosis of the infection caused by cryptococcus.
The currently used typing method can only conduct one-stage typing on cryptococcus, namely, can identify which of the molecular types in 8 belongs to cryptococcus, and cannot conduct two-stage typing. However, the means for realizing secondary typing such as QPCR is limited by expensive and complex instruments and equipment, and for hospitals in less developed areas, corresponding instruments and equipment and technicians cannot be equipped, so that accurate identification of secondary typing of cryptococcus is not possible.
In view of the above, the present application provides a method for identifying cryptococcus, which can be implemented without expensive instruments and complicated detection techniques, and can accurately identify cryptococcus subtypes, thereby helping to promote early diagnosis and treatment of cryptococcus.
Referring to FIG. 1, a schematic flow chart of a method 100 for identifying cryptococcus in accordance with an embodiment of the present application is shown. The method 100 comprises the following steps:
s101, obtaining genome DNA of a sample to be detected;
s102, amplifying URA5 genes of the genome DNA by PCR to obtain amplification products;
s103, performing sanger sequencing on the amplified product;
s104, determining the type of the cryptococcus according to 526-locus sequencing results of the URA5 gene.
Specifically, the present inventors found that secondary typing of cryptococcus can be judged by detecting whether mutation occurs in URA5 gene of cryptococcus by combining the previous results with computational biology method. The URA5 gene sequence of Cryptococcus VGIa is shown as Seq ID No.4, and the URA5 gene sequence of Cryptococcus wildtype is shown as Seq ID No. 3. Whether the cryptococcus is a type VGIa cryptococcus can be judged by whether mutation occurs at 562 locus of URA5 gene. Thus, the identification method 100 of the present application can achieve a two-level typing of cryptococcus by detecting mutation of URA5 gene. In addition, mutation of the URA5 gene can be detected only by combining sanger sequencing with MLST or other common molecular typing methods, and expensive testing instruments and complex testing technologies are not needed, so that medical staff in underdeveloped areas can accurately determine the secondary molecular typing of cryptococcus, and the detection cost of cryptococcus is effectively saved.
It is understood that wild-type cryptococcus in this application refers to other types of cryptococcus besides Cryptococcus of VGIa.
Optionally, in S104, determining the typing of cryptococcus based on the 562-locus sequencing result of URA5 gene comprises:
under the condition that 562 locus of URA5 gene is G, determining cryptococcus as VGIa type cryptococcus;
in the case where 562 locus of URA5 gene is A, C or T, cryptococcus is determined to be wild-type cryptococcus.
Specifically, the 562 locus of the URA5 gene of Cryptococcus VGIa is mutated to G. Therefore, by detecting 562 sites of the URA5 gene sequence of the sample to be detected, whether the cryptococcus in the sample to be detected is the VGIa type cryptococcus can be accurately judged, so that the subtype of the cryptococcus is effectively detected, and the judgment of the type of pathogenic cryptococcus is facilitated.
In some embodiments, the PCR reaction in S102 comprises: a URA5 forward primer and a URA5 reverse primer, wherein the nucleotide sequence of the URA5 forward primer is shown as Seq ID No.1, i.e., the nucleotide sequence of the ATGTCCTCCCAAGCCCTCGAC, URA reverse primer is shown as Seq ID No.2, i.e., TTAAGACCTCTGAACACCGTACTC.
FIG. 2 is another schematic flow chart of a method 100 for identifying cryptococcus in accordance with an embodiment of the present application.
Optionally, after obtaining the amplification product, the method 100 further comprises:
s105, confirming that URA5 gene amplification was successful.
Alternatively, in S105, success of URA5 gene amplification was confirmed by gel electrophoresis.
It is to be understood that the gel electrophoresis described herein includes, but is not limited to, agarose gel electrophoresis. In some other embodiments, the success of URA5 gene amplification can also be confirmed by polyacrylamide gel electrophoresis.
Specifically, the cryptococcus identification method 100 of the present application can perform gel electrophoresis on the amplified product after PCR amplification, thereby judging whether the amplification of the target gene URA5 is successful. If the amplification is successful, step S103 is executed, namely, the amplified product is subjected to sanger sequencing; if the amplification is unsuccessful, steps S101 and S102 are re-executed. By judging whether the target gene is amplified successfully, the reliability of the subsequent sanger sequencing can be improved, and the waste of sequencing time and sequencing cost caused by unsuccessful amplification of the target gene is avoided, so that the efficiency of identifying the cryptococcus molecular type is improved.
Optionally, in S101, obtaining genomic DNA of the sample to be tested includes:
grinding a sample to be detected by a liquid nitrogen grinding method; genomic DNA was extracted by standard phenol chloroform method.
The present application also uses a primer pair for identifying Cryptococcus VGIa type, which comprises a forward primer and a reverse primer, wherein the nucleotide sequence of the forward primer is shown as Seq ID No.1, and the nucleotide sequence of the reverse primer is shown as Seq ID No. 2.
Alternatively, the primer pair is used to identify position 562 of the URA5 gene sequence of cryptococcus. Specifically, the primer pair is capable of specifically recognizing the URA5 gene sequence of cryptococcus so that the 562 locus of the URA5 gene sequence is detected.
The application also provides a kit for identifying the Cryptococcus VGIa, which comprises the primer pair for identifying the Cryptococcus VGIa.
Optionally, the kit further comprises at least one of a buffer, a template DNA, deoxynucleoside triphosphate dntps, and a DNA polymerase.
In addition, the use of a primer pair as described above for identifying cryptococcus of the VGIa type in the identification of cryptococcus of the VGIa type.
Next, specific steps of the authentication method 100 provided in the present application are further described. It is to be understood that the following examples are merely illustrative of embodiments of the identification methods of the present application, wherein the specific reagent amounts or use of the apparatus may be adjusted as desired and are not to be construed as limiting the examples of the present application.
Example 1: extraction of genomic DNA
1. Test materials: sample to be measured
The sample to be tested described herein includes, but is not limited to, blood, body fluids, or lung tissue.
2. Main reagent and instrument
Reagents include, but are not limited to: liquid nitrogen, 100% alcohol, 75% alcohol, 50% alcohol, ultrapure water, DNA lysate, protease K, tris saturated phenol, chloroform, isoamyl alcohol.
Instruments include, but are not limited to: mortar, pipette, centrifuge, freeze dryer.
3. Experimental method
Get greater than 1 x 10 7 After liquid nitrogen milling in a mortar, genomic DNA was extracted using standard phenol chloroform DNA extraction procedure for each test bacterial sample.
The standard phenol chloroform extraction step may include the steps of:
1) And (3) placing the ground sample to be tested into a centrifuge tube, and respectively carrying out gradient dealcoholization by using 75% alcohol, 50% alcohol and ultrapure water. The dehydration time for each gradient was 5-10min.
2) The sample to be tested after step 1) is placed in a mortar, and an appropriate amount of DNA lysate, for example 300. Mu.L, is added.
3) The ground sample to be tested is transferred into a first centrifuge tube by a pipette, and an appropriate amount of proteinase K, for example 10. Mu.L, is added into the first centrifuge tube, and the first centrifuge tube is sealed and placed into a shaker (56 ℃ C., 5 h).
4) An equal volume of Tris saturated phenol was added to the first centrifuge tube and shaken well (10 min).
5) Putting the first centrifugal tube into a centrifugal machine for centrifugation, wherein the centrifugation conditions are as follows: 12000R,7min,4 ℃. After centrifugation, the mixture is divided into an upper layer, a middle layer and a lower layer, wherein the upper layer is DNA, the middle layer is protein, and the lower layer is organic matter.
6) The supernatant was pipetted and transferred into a second centrifuge tube, to which was added 450. Mu.L of a mixture of Tris-saturated phenol, chloroform and isoamyl alcohol and shaken for 10min. Wherein, the volume ratio of each component in the mixed solution is Tris saturated phenol: chloroform: isoamyl alcohol=25: 24:1.
7) Putting the second centrifugal tube into a centrifugal machine for centrifugation, wherein the centrifugation conditions are as follows: 12000R,7min,4 ℃.
8) Sucking the supernatant into a third centrifuge tube by using a pipette, and adding 400 mu L of a mixed solution of chloroform and isoamyl alcohol in equal volume, wherein the volume ratio of each component in the mixed solution is chloroform: isoamyl alcohol=24: 1.
9) Putting the third centrifugal tube into a centrifugal machine for centrifugation, wherein the centrifugation conditions are as follows: 12000R,7min,4 ℃.
10 Pipette the supernatant into a fourth centrifuge tube, add 2.5 volumes of 100% alcohol frozen at-20 ℃. Overnight at-20 ℃.
11 Placing the fourth centrifugal tube into a centrifugal machine for centrifugation, wherein the centrifugation conditions are as follows: 12000R,7min,4 ℃.
12 A white precipitate (DNA) at the bottom of the fourth centrifuge tube was left, 400. Mu.L of 75% alcohol frozen at-20℃was added thereto, and the mixture was repeatedly blown and dissolved.
13 Repeating step 12) twice.
14 Extracting genome DNA of the sample to be detected.
Example 2: PCR amplification reaction
1. Test materials: 10 ng/. Mu.L of genomic DNA, 10. Mu.M URA5 forward primer 2. Mu.L, 0. Mu.M URA5 reverse primer 2. Mu.L.
2. Main reagent and instrument
Reagents include, but are not limited to: ultrapure water, dNTPs, a buffer solution and DNA polymerase.
3. Experimental method
The PCR amplification reaction was performed using a PCR amplification kit of Prime STAR 2X Mix from TAKARA company, and the PCR amplification process can be seen in the product instructions of the kit. In this example, the nucleotide sequence of the URA5 forward primer is shown as Seq ID No.1 and the nucleotide sequence of the URA5 reverse primer is shown as Seq ID No. 2. Wherein the concentration of URA5 forward primer is 10. Mu.M.
Example 3: agarose gel electrophoresis
The amplification products of example 2 were subjected to agarose gel electrophoresis test, and the measured electrophoresis pattern is shown in FIG. 3. The single band can be known by electrophoresis pattern, and when the single band is the electrophoresis band with 638bp size, the next step of sequencing is performed.
Example 4: sanger sequencing and site analysis
1. Test materials: amplification products.
2. Main reagent and instrument
Reagents include, but are not limited to: ultrapure water, ddNTP, DNA polymerase.
Instruments include, but are not limited to: sequencer, centrifuge.
3. Experimental method
1) Purifying the amplified product;
2) The purified amplified product is subjected to a program reaction: pre-denaturation at 96 ℃ for 2min, followed by 25 cycles of the following steps: 96 ℃ for 10s;55 ℃ for 5s; and at 60℃for 90s. Finally cooling to 4 ℃ or 15 ℃.
3) After denaturation, the sample was sent to a sequencer for sequencing.
4. Analysis and judgment of amplification result
After the sequencing result is obtained, the 562 locus of the URA5 gene is analyzed, and the cryptococcus is typed according to the sequencing result of the locus.
In other words, when the 562 site of the URA5 gene is mutated to G, cryptococcus is determined to be cryptococcus of VGIa type;
when there is no mutation at position 562 of the URA5 gene, cryptococcus is determined to be wild-type cryptococcus.
The peak patterns of gene sequencing of wild-type cryptococcus and VGIa cryptococcus at position 562 are shown in FIG. 4. As can be seen from FIG. 4, cryptococcus VGIa differs significantly from Cryptococcus wild-type at 562 site, and the 562 site is mutated to G. Again, the 562 locus of the URA5 gene proved to be effective in identifying the subtype of cryptococcus, for example, cryptococcus VGIa.
In conclusion, the cryptococcus identification method can identify subspecies of cryptococcus by analyzing specific sites of the sanger sequencing result of the URA5 gene, so that the subtype of cryptococcus can be accurately judged. More specifically, it can be determined whether or not cryptococcus belongs to the type VGIa cryptococcus, and detection of the cryptococcus subtype can be achieved. Clinical data show that pathogenicity and mortality of cryptococcus of different subtypes are obviously different, so that the method is beneficial to rapidly and accurately identifying and diagnosing the infection caused by the cryptococcus when being applied to clinic, thereby improving a treatment scheme and reducing drug abuse; the technical scheme of the application is convenient to operate and easy to popularize, and has wide application prospect.
In the description of the present specification, the descriptions of the terms "one embodiment," "one implementation," "some embodiments," "an exemplary embodiment," "an example," "a particular example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present application. In this specification, schematic representations of the above terms do not necessarily refer to the same embodiments or examples. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present application, and not for limiting the same; although the present application has been described in detail with reference to the foregoing embodiments, it should be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the corresponding technical solutions from the scope of the technical solutions of the embodiments of the present application.
Claims (12)
1. A method of identifying cryptococcus, said method comprising:
obtaining genome DNA of a sample to be tested;
amplifying the URA5 gene of the genomic DNA by polymerase chain reaction PCR to obtain an amplified product;
performing sanger sequencing on the amplification product;
determining the type of the cryptococcus based on the 562-locus sequencing result of the URA5 gene.
2. The method of claim 1, wherein said determining the type of cryptococcus based on sequencing of position 562 of the URA5 gene comprises:
determining the cryptococcus as a VGIa type cryptococcus in the case that the 562 site of the URA5 gene is guanine G;
in the case where the 562 locus of the URA5 gene is adenine a, cytosine C or thymine T, the cryptococcus is determined to be a wild-type cryptococcus.
3. The method of claim 1 or 2, wherein the reactants of the PCR comprise URA5 forward primers and URA5 reverse primers; wherein the nucleotide sequence of the URA5 forward primer is shown as a Seq ID No.1, and the nucleotide sequence of the URA5 reverse primer is shown as a Seq ID No. 2.
4. The method of any one of claims 1-3, wherein after obtaining the amplification product, the method further comprises:
confirming that the URA5 gene amplification was successful.
5. The method of claim 4, wherein the success of the URA5 gene amplification is confirmed by gel electrophoresis.
6. The method of any one of claims 1-5, wherein the obtaining genomic DNA of the test sample comprises:
grinding the sample to be tested by a liquid nitrogen grinding method;
the genomic DNA was extracted by standard phenol chloroform method.
7. The method according to any one of claims 1-6, wherein the sample to be tested comprises blood and/or body fluid.
8. A primer pair for identifying cryptococcus of VGIa type, wherein the primer pair comprises a forward primer and a reverse primer, wherein the nucleotide sequence of the forward primer is shown as Seq ID No.1, and the nucleotide sequence of the reverse primer is shown as Seq ID No. 2.
9. The primer pair of claim 8, wherein the primer pair is used to recognize 562 locus of URA5 gene sequence of the cryptococcus.
10. A kit for identifying cryptococcus of VGIa type, characterized in that it comprises the primer pair of claim 8 or 9.
11. The kit of claim 10, further comprising: buffer solution, template DNA, deoxynucleoside triphosphate dNTPs and DNA polymerase.
12. Use of a primer pair according to claim 8 or 9 for the identification of cryptococcus VGIa.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310144307.8A CN116287388A (en) | 2023-02-17 | 2023-02-17 | Identification method, primer pair and kit for cryptococcus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310144307.8A CN116287388A (en) | 2023-02-17 | 2023-02-17 | Identification method, primer pair and kit for cryptococcus |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116287388A true CN116287388A (en) | 2023-06-23 |
Family
ID=86793393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310144307.8A Pending CN116287388A (en) | 2023-02-17 | 2023-02-17 | Identification method, primer pair and kit for cryptococcus |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116287388A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117089648A (en) * | 2023-10-11 | 2023-11-21 | 首都医科大学附属北京世纪坛医院 | Primer probe combination, method and kit for detecting VGIa type cryptococcus |
CN117106966A (en) * | 2023-10-11 | 2023-11-24 | 首都医科大学附属北京世纪坛医院 | Primer pair, method and kit for detecting cryptococcus garvieae |
CN117467791A (en) * | 2023-10-11 | 2024-01-30 | 首都医科大学附属北京世纪坛医院 | Primer pair, method and kit for detecting cryptococcus neoformans |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101974608A (en) * | 2010-08-10 | 2011-02-16 | 上海交通大学医学院附属新华医院 | Perilla seed culture medium and application thereof |
CN102876585A (en) * | 2012-09-19 | 2013-01-16 | 中国人民解放军第二军医大学 | Cryptococcus gattii, and isolated culture method and application thereof |
CN105168139A (en) * | 2015-09-15 | 2015-12-23 | 中国人民解放军第二军医大学 | Application of silver-coated-palladium nano preparation in preparing medicine for preventing cryptococcus infection |
WO2016016805A1 (en) * | 2014-08-01 | 2016-02-04 | Versalis S.P.A. | Gene construct for the transformation of yeast strains |
US20160040217A1 (en) * | 2014-08-06 | 2016-02-11 | The Translational Genomics Research Institute | Methods and kits to detect and genotype cryptococcus species |
JP2018046838A (en) * | 2017-10-25 | 2018-03-29 | 東洋紡株式会社 | Marker gene |
-
2023
- 2023-02-17 CN CN202310144307.8A patent/CN116287388A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101974608A (en) * | 2010-08-10 | 2011-02-16 | 上海交通大学医学院附属新华医院 | Perilla seed culture medium and application thereof |
CN102876585A (en) * | 2012-09-19 | 2013-01-16 | 中国人民解放军第二军医大学 | Cryptococcus gattii, and isolated culture method and application thereof |
WO2016016805A1 (en) * | 2014-08-01 | 2016-02-04 | Versalis S.P.A. | Gene construct for the transformation of yeast strains |
US20160040217A1 (en) * | 2014-08-06 | 2016-02-11 | The Translational Genomics Research Institute | Methods and kits to detect and genotype cryptococcus species |
US20180274011A1 (en) * | 2014-08-06 | 2018-09-27 | The Translational Genomics Research Institute | Methods and kits to detect and genotype cryptococcus species |
CN105168139A (en) * | 2015-09-15 | 2015-12-23 | 中国人民解放军第二军医大学 | Application of silver-coated-palladium nano preparation in preparing medicine for preventing cryptococcus infection |
JP2018046838A (en) * | 2017-10-25 | 2018-03-29 | 東洋紡株式会社 | Marker gene |
Non-Patent Citations (9)
Title |
---|
ANURADHA CHOWDHARY等: "Genetic differentiation, recombination and clonal expansion in environmental populations of Cryptococcus gattii in India", 《ENVIRON MICROBIOL》, vol. 13, no. 7, 1 June 2011 (2011-06-01), pages 1, XP072192948, DOI: 10.1111/j.1462-2920.2011.02510.x * |
NAICKER, S.D.等: "Cryptococcus gattii VGI isolate ID_123 orotidine monophosphate pyrophosphorylase (URA5) gene GenBank: OL908730.1", 《GENBANK》, 31 July 2022 (2022-07-31), pages 1 * |
WIELAND MEYER等: "Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii", 《MED MYCOL》, vol. 47, no. 6, 31 December 2019 (2019-12-31), pages 566 * |
WIELAND MEYER等: "Molecular typing of IberoAmerican Cryptococcus neoformans isolates", 《EMERG INFECT DIS》, vol. 9, no. 2, 28 February 2003 (2003-02-28), pages 190 - 191 * |
XINYING XUE等: "Cryptococcus gattii VGI Subtypes: Geographical Distribution, Molecular Traits, and Virulence Difference", 《RESEARCH SQUARE》, 5 November 2021 (2021-11-05), pages 1 - 11 * |
XINYING XUE等: "Cryptococcus gattii VGI Subtypes: Geographical Distribution, Molecular Traits, and Virulence Difference", 《RESEARCH SQUARE》, 5 October 2021 (2021-10-05), pages 1 - 11 * |
吴思颖等: "MALDI-TOF MS对新生隐球菌和格特隐球菌的快速鉴定与分析", 《国际检验医学杂志》, vol. 41, no. 14, 23 July 2020 (2020-07-23), pages 1699 - 1702 * |
吴绍熙: "《现代医学真菌检验手册 第2版》", 31 October 2005, 中国协和医科大社学出版, pages: 449 * |
窦红涛: "我国107株新生/格特隐球菌的基因型特点及DiversiLab系统在其基因分型中的应用", 《中国博士学位论文全文数据库 医药卫生科技辑》, 15 November 2015 (2015-11-15), pages 059 - 14 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117089648A (en) * | 2023-10-11 | 2023-11-21 | 首都医科大学附属北京世纪坛医院 | Primer probe combination, method and kit for detecting VGIa type cryptococcus |
CN117106966A (en) * | 2023-10-11 | 2023-11-24 | 首都医科大学附属北京世纪坛医院 | Primer pair, method and kit for detecting cryptococcus garvieae |
CN117467791A (en) * | 2023-10-11 | 2024-01-30 | 首都医科大学附属北京世纪坛医院 | Primer pair, method and kit for detecting cryptococcus neoformans |
CN117089648B (en) * | 2023-10-11 | 2024-07-19 | 首都医科大学附属北京世纪坛医院 | Primer probe combination, method and kit for detecting VGIa cryptococcus |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116287388A (en) | Identification method, primer pair and kit for cryptococcus | |
CN107849618A (en) | Differentiate and detect the genetic marker of aquatile infectious disease Causative virus and using its Causative virus discriminating and detection method | |
CN113355459B (en) | Method and kit for detecting and screening N501Y mutation of new coronavirus | |
CN110358815B (en) | Method for simultaneously detecting multiple target nucleic acids and kit thereof | |
CN107828914A (en) | Infectious subcutaneous and haematopoietic necrosis virus(IHHNV)RAA constant temperature fluorescence detection method and reagent | |
CN112359125A (en) | Method for rapidly detecting cryptococcus gatherensis | |
CN113481311A (en) | SNP molecular marker for identifying Brucella vaccine strain M5 and application thereof | |
CN116334280A (en) | Identification method, primer pair and kit for cryptococcus | |
CN116356064A (en) | Identification method, primer pair and kit for cryptococcus | |
CN113308575B (en) | Method and kit for detecting and screening N439K mutation of new coronavirus | |
CN113699276B (en) | Novel coronavirus 5 point mutation S gene identification kit based on high-resolution melting curve and identification method thereof | |
CN114634996A (en) | Primer-probe combination for detecting bovine respiratory diseases, kit and application thereof | |
CN110592215A (en) | Composition for detecting nucleic acid sequence and detection method | |
CN106319079B (en) | Method for detecting 22q11.2 copy number loss | |
CN109735645B (en) | Real-time fluorescent PCR (polymerase chain reaction) primer, probe and kit for detecting Sporothrix globosum | |
CN115786541B (en) | SNP molecular marker, primer probe, kit, method and application for identifying Brucella vaccine strain A19 | |
CN111549109A (en) | High-throughput pathogen microorganism gene detection screening method | |
CN110592269A (en) | RAA constant-temperature fluorescence detection method and reagent for grass carp hemorrhagic disease type 2 virus (GCRV-2) | |
CN114085924B (en) | Novel coronavirus 4 point mutation S gene identification kit based on high-resolution melting curve and identification method thereof | |
CN115927749A (en) | Method and kit for detecting and screening L452R mutation and T478K mutation of Delta strain of new coronavirus | |
KR102076343B1 (en) | Composition for detecting adenovirus type 55 using Real-time LAMP and uses thereof | |
KR101617142B1 (en) | Nucleic acid test based avian influenza virus detection kit with improved detection accuracy | |
CN110894551A (en) | RAA constant-temperature fluorescence detection method and reagent for grass carp hemorrhagic disease type I virus (GCRV-I) | |
TWI646198B (en) | Method for screening high risk of liver cancer by using hepatitis B virus gene sequence | |
CN110894549A (en) | RAA constant temperature fluorescence detection method and reagent for Epidemic Hematopoietic Necrosis Virus (EHNV) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |